Chemical Formula: C9H14N4O5

Chemical Formula C9H14N4O5

Found 20 metabolite its formula value is C9H14N4O5

AICA-riboside

5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4-carboxamide

C9H14N4O5 (258.0964154)


AICA-riboside, also known as acadesine or AICAR, is an AMP-activated protein kinase activator which is used for the treatment of acute lymphoblastic leukemia and may have applications in treating other disorders such as diabetes. AICA-riboside is an adenosine regulating agent developed by PeriCor Therapeutics and licensed to Schering-Plough in 2007 for phase III studies. The drug is a potential first-in-class agent for prevention of reperfusion injury in CABG surgery. Schering began patient enrollment in phase III studies in May, 2009. The trial was terminated in late 2010 based on an interim futility analysis (Wikipedia). AICA-riboside is a minor constituent found in human milk (PMID: 7702711). C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C - Cardiovascular system > C01 - Cardiac therapy D007004 - Hypoglycemic Agents

   

1H-Imidazole-1-acetamide, N,N-bis(2-hydroxyethyl)-2-nitro-

N,N-bis(2-hydroxyethyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide

C9H14N4O5 (258.0964154)


   

5-Amino-1-[(2R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carboxamide

5-Amino-1-[(2R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carboxamide

C9H14N4O5 (258.0964154)


   

Ribosyl-5-amino-4-imidazolcarboxamid

5-Amino-2-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4-carboximidate

C9H14N4O5 (258.0964154)


   

(5-Amino-imidazol-4-carbonsaeureamid)-ribofuranosid|5-amino-1(3)H-imidazole-4-carboxylic acid beta-D-ribofuranosylamide

(5-Amino-imidazol-4-carbonsaeureamid)-ribofuranosid|5-amino-1(3)H-imidazole-4-carboxylic acid beta-D-ribofuranosylamide

C9H14N4O5 (258.0964154)


   

AICA-riboside; LC-tDDA; CE30

AICA-riboside; LC-tDDA; CE30

C9H14N4O5 (258.0964154)


   

AICA-riboside; LC-tDDA; CE10

AICA-riboside; LC-tDDA; CE10

C9H14N4O5 (258.0964154)


   

AICA-riboside; LC-tDDA; CE20

AICA-riboside; LC-tDDA; CE20

C9H14N4O5 (258.0964154)


   

AICA-riboside; LC-tDDA; CE40

AICA-riboside; LC-tDDA; CE40

C9H14N4O5 (258.0964154)


   

AICA-riboside; AIF; CE0; CorrDec

AICA-riboside; AIF; CE0; CorrDec

C9H14N4O5 (258.0964154)


   

AICA-riboside; AIF; CE10; CorrDec

AICA-riboside; AIF; CE10; CorrDec

C9H14N4O5 (258.0964154)


   

AICA-riboside; AIF; CE30; CorrDec

AICA-riboside; AIF; CE30; CorrDec

C9H14N4O5 (258.0964154)


   

AICA-riboside; AIF; CE0; MS2Dec

AICA-riboside; AIF; CE0; MS2Dec

C9H14N4O5 (258.0964154)


   

AICA-riboside; AIF; CE10; MS2Dec

AICA-riboside; AIF; CE10; MS2Dec

C9H14N4O5 (258.0964154)


   

AICA-riboside; AIF; CE30; MS2Dec

AICA-riboside; AIF; CE30; MS2Dec

C9H14N4O5 (258.0964154)


   

5-AMINOIMIDAZOLE-4-CARBOXAMIDE-1-BETA-RIBOFURANOSIDE

5-AMINOIMIDAZOLE-4-CARBOXAMIDE-1-BETA-RIBOFURANOSIDE

C9H14N4O5 (258.0964154)


   

Acadesine

5-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carboxamide

C9H14N4O5 (258.0964154)


C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C - Cardiovascular system > C01 - Cardiac therapy

   

4-amino-2-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-5-carboxamide

4-amino-2-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-5-carboxamide

C9H14N4O5 (258.0964154)


   

5-amino-1-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-4-imidazolecarboxamide

5-amino-1-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-4-imidazolecarboxamide

C9H14N4O5 (258.0964154)


   

AICAR

AICAR

C9H14N4O5 (258.0964154)


D007004 - Hypoglycemic Agents